Robert C Bourge1, Aaron B Waxman2, Mardi Gomberg-Maitland3, Shelley M Shapiro4, James H Tarver5, Dianne L Zwicke6, Jeremy P Feldman7, Murali M Chakinala8, Robert P Frantz9, Fernando Torres10, Jeffrey Cerkvenik11, Marty Morris11, Melissa Thalin11, Leigh Peterson12, Lewis J Rubin13. 1. University of Alabama at Birmingham, Birmingham, AL. Electronic address: bbourge@uab.edu. 2. Brigham & Women's Hospital, Boston, MA. 3. University of Chicago Medical Center, Chicago, IL. 4. VA Greater Los Angeles Healthcare System and UCLA School of Medicine, Los Angeles, CA. 5. Orlando Regional Medical Center, Orlando, FL. 6. Aurora St. Luke's Medical Center, Milwaukee, WI. 7. Arizona Pulmonary Specialists, Ltd, St. Louis, MO. 8. Washington University School of Medicine, St. Louis, MO. 9. Mayo Clinic Rochester, Rochester, MN. 10. University of Texas Southwestern Medical Center, Rochester, MN. 11. Medtronic, Inc, Minneapolis, MN. 12. United Therapeutics Corporation, Research Triangle Park, NC. 13. UC San Diego Division of Pulmonary & Critical Care Medicine, La Jolla, CA.
Abstract
BACKGROUND: The use of systemic prostanoids in severe pulmonary arterial hypertension (PAH) is often limited by patient/physician dissatisfaction with the delivery methods. Complications associated with external pump-delivered continuous therapy include IV catheter-related bloodstream infections and subcutaneous infusion site pain. We therefore investigated a fully implantable intravascular delivery system for treprostinil infusion. METHODS: A multicenter, prospective, single-arm, clinical trial (DelIVery for Pulmonary Arterial Hypertension) was conducted by using an implantable intravascular delivery system. The implanted pumps were refilled percutaneously at least every 12 weeks. The primary end point was the rate of catheter-related complications using the new model 10642 catheter compared with a predefined objective performance criterion of 2.5 per 1,000 patient-days based on the literature. RESULTS: Patients (n = 60) with severe PAH (World Health Organization group 1) receiving a stable dose of IV treprostinil for at least 4 weeks received an implant device and were followed up for 12.1 ± 4.4 months. Six catheter-related complications occurred, corresponding to a complication rate of 0.27 per 1,000 patient-days. The 97.5% upper one-sided confidence bound of 0.59 was less than the predefined criterion of 2.5 per 1,000 patient-days (P < .0001). Plasma treprostinil levels at 1 week postimplantation were highly correlated with baseline levels (r = 0.91; P < .0001). The delivery system management time as reported by the patients was 2.5 ± 1.7 hours per week preimplantation, and this time decreased to 0.6 ± 0.8 hour per week at 6 months' postimplantation (P < .0001). All patients rated overall satisfaction with the implantable system as good, very good, or excellent at 6 weeks and 6 months. There were no catheter-related bloodstream infections or catheter occlusions. CONCLUSIONS: The implantable intravascular delivery system delivered treprostinil to patients with PAH with a low rate of catheter-related complications and a high rate of patient satisfaction. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01321073; URL: www.clinicaltrials.gov.
BACKGROUND: The use of systemic prostanoids in severe pulmonary arterial hypertension (PAH) is often limited by patient/physician dissatisfaction with the delivery methods. Complications associated with external pump-delivered continuous therapy include IV catheter-related bloodstream infections and subcutaneous infusion site pain. We therefore investigated a fully implantable intravascular delivery system for treprostinil infusion. METHODS: A multicenter, prospective, single-arm, clinical trial (DelIVery for Pulmonary Arterial Hypertension) was conducted by using an implantable intravascular delivery system. The implanted pumps were refilled percutaneously at least every 12 weeks. The primary end point was the rate of catheter-related complications using the new model 10642 catheter compared with a predefined objective performance criterion of 2.5 per 1,000 patient-days based on the literature. RESULTS:Patients (n = 60) with severe PAH (World Health Organization group 1) receiving a stable dose of IV treprostinil for at least 4 weeks received an implant device and were followed up for 12.1 ± 4.4 months. Six catheter-related complications occurred, corresponding to a complication rate of 0.27 per 1,000 patient-days. The 97.5% upper one-sided confidence bound of 0.59 was less than the predefined criterion of 2.5 per 1,000 patient-days (P < .0001). Plasma treprostinil levels at 1 week postimplantation were highly correlated with baseline levels (r = 0.91; P < .0001). The delivery system management time as reported by the patients was 2.5 ± 1.7 hours per week preimplantation, and this time decreased to 0.6 ± 0.8 hour per week at 6 months' postimplantation (P < .0001). All patients rated overall satisfaction with the implantable system as good, very good, or excellent at 6 weeks and 6 months. There were no catheter-related bloodstream infections or catheter occlusions. CONCLUSIONS: The implantable intravascular delivery system delivered treprostinil to patients with PAH with a low rate of catheter-related complications and a high rate of patient satisfaction. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01321073; URL: www.clinicaltrials.gov.
Authors: Ralf Ewert; Manuel J Richter; Regina Steringer-Mascherbauer; Ekkehard Grünig; Tobias J Lange; Christian F Opitz; Christian Warnke; Hossein-Ardeschir Ghofrani Journal: Clin Res Cardiol Date: 2017-04-20 Impact factor: 5.460
Authors: Manuel J Richter; Ralf Ewert; Christian Warnke; Henning Gall; Simon Classen; Friedrich Grimminger; Eckhard Mayer; Werner Seeger; Hossein-Ardeschir Ghofrani Journal: Clin Res Cardiol Date: 2016-09-26 Impact factor: 5.460
Authors: Mardi Gomberg-Maitland; Robert C Bourge; Shelley M Shapiro; James H Tarver; Dianne L Zwicke; Jeremy P Feldman; Murali M Chakinala; Robert P Frantz; Fernando Torres; Remzi Bag; Jeffrey A Murphy; Amy A Lautenbach; Marty Morris; Leigh Peterson; Aaron B Waxman Journal: Pulm Circ Date: 2019-11-05 Impact factor: 3.017
Authors: Shelley Shapiro; Robert C Bourge; Patti Pozella; David F Harris; Erick H Borg; Andrew C Nelsen Journal: Pulm Circ Date: 2020-04-22 Impact factor: 3.017
Authors: Marcin Kurzyna; Katarzyna Małaczyńska-Rajpold; Andrzej Koteja; Agnieszka Pawlak; Łukasz Chrzanowski; Michał Furdal; Zbigniew Gąsior; Wojciech Jacheć; Bożena Sobkowicz; Justyna Norwa; Tatiana Mularek-Kubzdela; Adam Torbicki Journal: BMC Pulm Med Date: 2017-12-02 Impact factor: 3.317
Authors: Evan W Davies; Samuel Llewellyn; Amélie Beaudet; Charlotte E Kosmas; Wendy Gin-Sing; Helen A Doll Journal: Patient Prefer Adherence Date: 2018-06-21 Impact factor: 2.711
Authors: Manuel J Richter; Satenik Harutyunova; Tom Bollmann; Simon Classen; Jan Fuge; Henning Gall; Felix Gerhardt; Hossein A Ghofrani; Hartmut Gunkel; Ekkehard Grünig; Michael Halank; Alexander Heine; Hans Klose; Tobias J Lange; Claus Neurohr; Kai Nickolaus; Christian F Opitz; Stephan Rosenkranz; Hans-Jürgen Seyfarth; Khodr Tello; Ralf Ewert; Karen M Olsson Journal: Pulm Circ Date: 2020-03-13 Impact factor: 3.017